tiprankstipranks
Trending News
More News >

Jiangzhong Pharmaceutical Reports Q1 2025 Financial Results

Story Highlights
  • Jiangzhong Pharmaceutical reported a slight revenue decrease but increased net profit in Q1 2025.
  • The company showed a strong financial position with increased cash and total assets.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.

China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has provided an update.

Jiangzhong Pharmaceutical, a subsidiary of China Resources Pharmaceutical Group Ltd., reported its unaudited financial results for the first quarter of 2025, showing a slight decrease in revenue but an increase in net profit compared to the previous year. The financial report highlights a net increase in cash and cash equivalents, along with a rise in total assets and owner’s equity, indicating a strong financial position despite the revenue dip. Stakeholders are advised to exercise caution as the financials are unaudited and may be subject to adjustments.

More about China Resources Pharmaceutical Group Ltd.

China Resources Pharmaceutical Group Ltd. operates in the pharmaceutical industry, focusing on the production and distribution of pharmaceutical products. It holds a significant equity interest in Jiangzhong Pharmaceutical, a company listed on the Shanghai Stock Exchange, which is a key player in the Chinese pharmaceutical market.

YTD Price Performance: -19.26%

Average Trading Volume: 1,550

Technical Sentiment Signal: Buy

Current Market Cap: €3.5B

See more insights into 3320 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App